Clinical trial
Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon
NCT00378521 · MediQuest Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00378521 |
|---|---|
| Title | Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon |
| Official title | Phase II Dose Response Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud's Phenomenon |
| Lead sponsor | MediQuest Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma, Raynaud's Disease Secondary to Autoimmune Disease |
| Intervention type | Drug |
| Interventions | MQX-503 |
| Enrollment | 15 |
| Start date | Jul 1, 2006 |
| Completion | Jul 1, 2006 |
| First posted | Sep 20, 2006 |
| Last update posted | May 30, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: